MoonLake Faces Multiple Securities Class Actions as Investor Lead-Plaintiff Deadline Nears
Plaintiffs cite MoonLake’s Phase 3 VELA disclosure followed by a near‑90% share drop as evidence of alleged misstatements about sonelokimab’s Nanobody claims.
Overview
- Bleichmar Fonti & Auld filed Peters v. MoonLake Immunotherapeutics, No. 1:25-cv-08612, in the Southern District of New York alleging violations of Sections 10(b) and 20(a).
- Berger Montague announced a separate action covering trades from March 10, 2024 through September 29, 2025, with a December 15, 2025 deadline to seek lead-plaintiff status.
- A Benzinga notice reports another case, Bridgewood v. MoonLake, No. 1:25-cv-08500, as Hagens Berman investigates statements about trial design and efficacy.
- The complaints focus on claims that MoonLake overstated sonelokimab’s Nanobody-derived advantages over monoclonal therapies such as FDA-approved BIMZELX.
- MoonLake’s September 28, 2025 update showed VELA-2 missed its primary endpoint, and shares fell about $55.75, or nearly 90%, on the next trading day.